Efficacy of a new cream formulation of mupirocin: Comparison with oral and topical agents in experimental skin infections

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 255-260

  Gisby, John ^a   Bryant, Joanna ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CICATRIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDATE SODIUM; NEBACETIN; PSEUDOMONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CREAM; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HAMSTER; IMPETIGO; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; WOUND INFECTION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACITRACIN; CEPHALEXIN; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; ERYTHROMYCIN; FEMALE; FLOXACILLIN; FUSIDIC ACID; IMPETIGO; MALE; MICE; MUPIROCIN; NEOMYCIN; PENICILLINS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; WOUND INFECTION;

EID: 0033972012     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.255-260.2000     Document Type: Article

References (43)

1. Atherton, D. J. 1996. The clinical efficacy of mupirocin in the treatment of primary skin infections, p. 25-36. In K. Bork (ed.), International clinical practice series: the clinical efficacy of mupirocin in the treatment of primary and secondary skin infections. Wells Medical Ltd., Tunbridge Wells, England.
2. Ayliffe, G. A., W. Green, R. Livingston, and E. J. L. Lowbury. 1977. Antibiotic-resistant Staphylococcus aureus in dermatology and burn wards. J. Clin. Pathol. 30:40-44.
3. Barr, J. G., and G. M. Hogg. 1987. Value of charcoal media for recovering staphylococci incorporated in mupirocin ointment. J. Clin. Pathol. 40:372-376.
4. Barton, L. L., and A. D. Friedman. 1987. Impetigo: a reassessment of etiology and therapy. Pediatr. Dermatol. 4:185-188.
5. Beale, A. S., J. Gisby, and R. Sutherland. 1989. Efficacy of mupirocin calcium in the treatment of experimental wound infections caused by methicillin-resistant strains of Staphylococcus aureus. J. Chemother. 4(Suppl. 1):397-398.
6. Boon, R. J., and A. S. Beale. 1987. Response of Streptococcus pyogenes to therapy with amoxicillin or amoxicillin-clavulanic acid in a mouse model of mixed infection caused by Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 31:1204-1209.
7. Bork, K., J. Brauers, and M. Kresken. 1989. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections - an open multicentre trial. Br. J. Clin. Pract. 43:284-288.
8. Britton, J. W., J. E. Fajardo, and B. Krafte-Jacobs. 1990. Comparison of mupirocin and erythromycin in the treatment of impetigo. J. Paediatr. 117: 827-829.
9. Casewell, M. W., and R. L. R. Hill. 1991. Minimal dose requirements for nasal mupirocin and role in the control of epidemic MRSA. J. Hosp. Infect. 19(Suppl. B):35-40.
10. Cockburn, J., R. W. Gibberd, A. L. Reid, and R. W. Sanson-Fisher. 1987. Determinants of noncompliance with short-term antibiotic regimens. Br. Med. J. Clin. Res. 295:814-818.
11. Cookson, B. D., R. W. Lacey, W. C. Noble, D. S. Reeves, R. Wise, and R. J. Redhead. 1990. Mupirocin-resistant Staphylococcus aureus. Lancet 335:1095-1096.
12. Cushing, A. H., and E. A. Mortimer. 1970. A hamster model of streptococcal impetigo. J. Infect. Dis. 122:224-226.
13. Dagan, R., and Y. Bar-David. 1992. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 36:287-290.
14. Dajani, A. S., P. L. Hill, and L. W. Wannamaker. 1971. Experimental infection of the hamster simulating human impetigo. II. Assessment of various therapeutic regimens. Pediatrics 48:83-90.
15. Dajani, A. S., and L. W. Wannamaker. 1970. Experimental infection of the skin in the hamster simulating human impetigo. I. Natural history of the infection. J. Infect. Dis. 122:196-204.
16. Demidovich, C. W., R. R. Wittler, M. E. Ruff, J. W. Bass, and W. C. Browning. 1990. Impetigo. Current etiology and comparison of penicillin, erythromycin and cephalexin therapies. Am. J. Dis. Child. 144:1313-1315.
17. Doebbeling, B. N., D. L. Breneman, H. C. Neu, and R. Aly. 1993. Elimination of S. aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin. Infect. Dis. 17:466-474.
18. Fernandez, C., C. Gaspar, A. Torrellas, A. Vindel, J. A. Saez-Nieto, F. Cruzet, and L. Aguilar. 1995 A double-blind, randomised, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of S. aureus among hospital personnel. J. Antimicrob. Chemother. 35:399-408.
19. Fuller, A. T., G. Mellows, M. Woolford, G. T. Banks, K. D. Barrow, and E. B. Chain. 1971. Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature 234:416-417.
20. Gilbert, M. 1989. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J. Am. Acad. Dermatol. 20:1083-1087.
21. Goldfarb, J., D. Crenshaw, J. O'Horo, E. Lemon, and J. L. Blumer. 1988. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob. Agents Chemother. 32:1780-1783.
22. Hughes, J., and G. Mellows. 1978. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J. Antibiot. 31:330-335.
23. Korzeniowski, O. M., W. M. Scheld, and M. A. Sande. 1977. Comparative pharmacology of cefaclor and cephalexin. Antimicrob. Agents Chemother. 12:157-162.
24. Langdon, C. G., and K. S. Mahapatra. 1990. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in superficial skin sepsis. Curr. Med. Res. 48:174-180.
25. Leyden, J. J. 1985. Studies on the safety of Bactroban ointment: potential for contact allergy, contact irritation, phototoxicity and photo-allergy. Excerpta Medica Curr. Clin. Pract. Ser. 16:68-71.
26. Maddin, S., S. Larochelle, R. D. Wilkinson, W. D. Carey, D. Gratton, and R. P. Haydey. 1987. Bactroban: efficacy and tolerance of a novel, new topical antibiotic vs. conventional systemic and topical treatment of primary and secondary skin infections. Contemp. Dermatol. June-July:32-39.
27. Männistö, P. T., J. Taskinen, P. Ottoila, A. Solkinen, A. Vuorela, and S. Nykanen. 1988. Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectroscopy in plasma of healthy human volunteers. J. Antimicrob. Chemother. 21(Suppl. D):33-43.
28. McLinn, S. 1990. A bacteriologically controlled, randomised study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J. Am. Acad. Dermatol. 22:883-885.
29. McRipley, R. J., and R. R. Whitney. 1976. Characterization and quantitation of experimental wound infections used to evaluate topical antibacterial agents. Antimicrob. Agents Chemother. 10:38-44.
30. Morley, P. A. R., and L. D. Munot. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr. Med. Res. Opin. 11:142-148.
31. Noble, W. C., and J. Naidoo. 1978. Evolution of antibiotic resistance in Staphylococcus aureus: the role of the skin. Br. J. Dermatol. 98:481-489.
32. Rice, T. D., A. K. Duggan, and C. DeAngelis. 1990. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Am. J. Child. 144:443-444.
33. Rogers, M., D. C. Dorman, M. Gapes, and J. A. M. Ly. 1987. A three-year study of impetigo in Sydney. Med. J. Aust. 147:63-65.
34. Shanson, D. C. 1990. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. J. Antimicrob. Chemother. 25(Suppl. B):15-21.
35. Sutherland, R., R. J. Boon, K. E. Griffin, P. J. Masters, B. Slocombe, and A. R. White. 1985. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob. Agents Chemother. 27:495-498.
36. Sutherland, R., E. A. P. Croydon, and G. N. Rolinson. 1970. Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin and dicloxacillin. Br. Med. J. 4:455-460.
37. Tasker, T. C. G., and D. Jackson. 1984. Clinical pharmacology of mupirocin, p. 173-180. In D. S. Wilkinson and J. D. Price (ed.), Mupirocin - a novel topical antibiotic. Royal Society of Medicine, London, England.
38. Villiger, J. W., W. D. Robertson, K. Kanji, M. Ah Chan, J. Fetherston, I. K. Hague, D. Haycock, and P. Hunter. 1986. A comparison of the new topical antibiotic mupirocin (Bactroban) with oral antibiotics in the treatment of skin infections in general practice. Curr. Med. Res. Opin. 10:339-345.
39. Wainscott, G. 1984. The use of mupirocin: an overview, p. 173-180. In D. S. Wilkinson and J. D. Price (ed.), Mupirocin - a novel topical antibiotic. Royal Society of Medicine, London, England.
40. White, A. R., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, and R. Sutherland. 1984. Antibacterial activity of mupirocin, an antibiotic produced by Pseudomonas fluorescens, p. 43-55. In D. S. Wilkinson and J. D. Price (ed.), Mupirocin - a novel topical antibiotic. Royal Society of Medicine, London, England.
41. White, D. G., P. O. Collins, and R. B. Rowsell. 1989. Topical antibiotics in the treatment of superficial skin infections in general practice - a comparison of mupirocin and sodium fusidate. J. Infect. 18:221-229.
42. White, J., B. J. Davies, M. Go, J. Lambers, D. Jackson, and G. Mellows. 1983. Pseudomonic acid: a new topical antibacterial agent. Lancet ii:394.
43. Wilkinson, R. D., and W. D. Carey. 1988. Topical mupirocin versus topical neosporin in the treatment of cutaneous infections. Int. J. Dermatol. 27:514-515.